MovDisordV3, PascalFrancis, Corpus, bibRecord, 002587

Entacapone-induced hepatotoxicity and hepatic dysfunction

Identifieur interne : 002587 ( PascalFrancis/Corpus ); précédent : 002586; suivant : 002588

Entacapone-induced hepatotoxicity and hepatic dysfunction

Auteurs : Alexander Fisher ; James Croft-Baker ; Michael Davis ; Patrick Purcell ; Allan J. Mclean

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:03-0038722

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Entacapone, Antiparkinsonien, Inhibiteur enzyme, Catechol O-methyltransferase, Foie pathologie, Etude cas, Toxicité, Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Case study, Catechol O-methyltransferase, Entacapone, Enzyme inhibitor, Hepatic disease, Human, Parkinson disease, Toxicity.

Abstract

We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Entacapone-induced hepatotoxicity and hepatic dysfunction`
A11	`01`	`1`		`@1 FISHER (Alexander)`
A11	`02`	`1`		`@1 CROFT-BAKER (James)`
A11	`03`	`1`		`@1 DAVIS (Michael)`
A11	`04`	`1`		`@1 PURCELL (Patrick)`
A11	`05`	`1`		`@1 MCLEAN (Allan J.)`
A14	`01`			`@1 Department of Geriatric Medicine, The Canberra Hospital @2 Canberra @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 Canberra Clinical School of the University of Sydney @2 Canberra @3 AUS @Z 3 aut.`
A14	`03`			`@1 Therapeutic Goods Administration @2 Canberra @3 AUS @Z 4 aut. @Z 5 aut.`
A14	`04`			`@1 National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health @2 Melbourne @3 AUS @Z 5 aut.`
A20				`@1 1362-1365`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000105559450350`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 03-0038722`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.`
C02	`01`	`X`		`@0 002B02U01`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 235`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Entacapone @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Entacapone @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Entacapona @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 05`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 05`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 05`
C03	`04`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 07`
C03	`04`	`X`	`ENG`	`@0 Enzyme inhibitor @5 07`
C03	`04`	`X`	`SPA`	`@0 Inhibidor enzima @5 07`
C03	`05`	`X`	`FRE`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`05`	`X`	`ENG`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`05`	`X`	`SPA`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`06`	`X`	`FRE`	`@0 Foie pathologie @5 10`
C03	`06`	`X`	`ENG`	`@0 Hepatic disease @5 10`
C03	`06`	`X`	`SPA`	`@0 Hígado patología @5 10`
C03	`07`	`X`	`FRE`	`@0 Etude cas @5 16`
C03	`07`	`X`	`ENG`	`@0 Case study @5 16`
C03	`07`	`X`	`SPA`	`@0 Estudio caso @5 16`
C03	`08`	`X`	`FRE`	`@0 Toxicité @5 17`
C03	`08`	`X`	`ENG`	`@0 Toxicity @5 17`
C03	`08`	`X`	`SPA`	`@0 Toxicidad @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Methyltransferases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Enzyme`
C07	`03`	`X`	`ENG`	`@0 Enzyme`
C07	`03`	`X`	`SPA`	`@0 Enzima`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`09`	`X`	`FRE`	`@0 Appareil digestif pathologie @5 61`
C07	`09`	`X`	`ENG`	`@0 Digestive diseases @5 61`
C07	`09`	`X`	`SPA`	`@0 Aparato digestivo patología @5 61`
N21				`@1 020`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0038722 INIST
ET :	Entacapone-induced hepatotoxicity and hepatic dysfunction
AU :	FISHER (Alexander); CROFT-BAKER (James); DAVIS (Michael); PURCELL (Patrick); MCLEAN (Allan J.)
AF :	Department of Geriatric Medicine, The Canberra Hospital/Canberra/Australie (1 aut., 2 aut., 3 aut., 5 aut.); Canberra Clinical School of the University of Sydney/Canberra/Australie (3 aut.); Therapeutic Goods Administration/Canberra/Australie (4 aut., 5 aut.); National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health/Melbourne/Australie (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 6; Pp. 1362-1365; Bibl. 20 ref.
LA :	Anglais
EA :	We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.
CC :	002B02U01; 002B17G; 235
FD :	Parkinson maladie; Entacapone; Antiparkinsonien; Inhibiteur enzyme; Catechol O-methyltransferase; Foie pathologie; Etude cas; Toxicité; Homme
FG :	Methyltransferases; Transferases; Enzyme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil digestif pathologie
ED :	Parkinson disease; Entacapone; Antiparkinson agent; Enzyme inhibitor; Catechol O-methyltransferase; Hepatic disease; Case study; Toxicity; Human
EG :	Methyltransferases; Transferases; Enzyme; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Digestive diseases
SD :	Parkinson enfermedad; Entacapona; Antiparkinsoniano; Inhibidor enzima; Catechol O-methyltransferase; Hígado patología; Estudio caso; Toxicidad; Hombre
LO :	INIST-20953.354000105559450350
ID :	03-0038722

Links to Exploration step

Pascal:03-0038722

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Entacapone-induced hepatotoxicity and hepatic dysfunction</title>
<author><name sortKey="Fisher, Alexander" sort="Fisher, Alexander" uniqKey="Fisher A" first="Alexander" last="Fisher">Alexander Fisher</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Croft Baker, James" sort="Croft Baker, James" uniqKey="Croft Baker J" first="James" last="Croft-Baker">James Croft-Baker</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Davis, Michael" sort="Davis, Michael" uniqKey="Davis M" first="Michael" last="Davis">Michael Davis</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Canberra Clinical School of the University of Sydney</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Purcell, Patrick" sort="Purcell, Patrick" uniqKey="Purcell P" first="Patrick" last="Purcell">Patrick Purcell</name>
<affiliation><inist:fA14 i1="03"><s1>Therapeutic Goods Administration</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mclean, Allan J" sort="Mclean, Allan J" uniqKey="Mclean A" first="Allan J." last="Mclean">Allan J. Mclean</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Therapeutic Goods Administration</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0038722</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0038722 INIST</idno>
<idno type="RBID">Pascal:03-0038722</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002587</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Entacapone-induced hepatotoxicity and hepatic dysfunction</title>
<author><name sortKey="Fisher, Alexander" sort="Fisher, Alexander" uniqKey="Fisher A" first="Alexander" last="Fisher">Alexander Fisher</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Croft Baker, James" sort="Croft Baker, James" uniqKey="Croft Baker J" first="James" last="Croft-Baker">James Croft-Baker</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Davis, Michael" sort="Davis, Michael" uniqKey="Davis M" first="Michael" last="Davis">Michael Davis</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Canberra Clinical School of the University of Sydney</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Purcell, Patrick" sort="Purcell, Patrick" uniqKey="Purcell P" first="Patrick" last="Purcell">Patrick Purcell</name>
<affiliation><inist:fA14 i1="03"><s1>Therapeutic Goods Administration</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mclean, Allan J" sort="Mclean, Allan J" uniqKey="Mclean A" first="Allan J." last="Mclean">Allan J. Mclean</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Therapeutic Goods Administration</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Case study</term>
<term>Catechol O-methyltransferase</term>
<term>Entacapone</term>
<term>Enzyme inhibitor</term>
<term>Hepatic disease</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Entacapone</term>
<term>Antiparkinsonien</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Foie pathologie</term>
<term>Etude cas</term>
<term>Toxicité</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Entacapone-induced hepatotoxicity and hepatic dysfunction</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FISHER (Alexander)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CROFT-BAKER (James)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DAVIS (Michael)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PURCELL (Patrick)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MCLEAN (Allan J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Geriatric Medicine, The Canberra Hospital</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Canberra Clinical School of the University of Sydney</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Therapeutic Goods Administration</s1>
<s2>Canberra</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>1362-1365</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000105559450350</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0038722</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Entacapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Foie pathologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>61</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>61</s5>
</fC07>
<fN21><s1>020</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0038722 INIST</NO>
<ET>Entacapone-induced hepatotoxicity and hepatic dysfunction</ET>
<AU>FISHER (Alexander); CROFT-BAKER (James); DAVIS (Michael); PURCELL (Patrick); MCLEAN (Allan J.)</AU>
<AF>Department of Geriatric Medicine, The Canberra Hospital/Canberra/Australie (1 aut., 2 aut., 3 aut., 5 aut.); Canberra Clinical School of the University of Sydney/Canberra/Australie (3 aut.); Therapeutic Goods Administration/Canberra/Australie (4 aut., 5 aut.); National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health/Melbourne/Australie (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 6; Pp. 1362-1365; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.</EA>
<CC>002B02U01; 002B17G; 235</CC>
<FD>Parkinson maladie; Entacapone; Antiparkinsonien; Inhibiteur enzyme; Catechol O-methyltransferase; Foie pathologie; Etude cas; Toxicité; Homme</FD>
<FG>Methyltransferases; Transferases; Enzyme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil digestif pathologie</FG>
<ED>Parkinson disease; Entacapone; Antiparkinson agent; Enzyme inhibitor; Catechol O-methyltransferase; Hepatic disease; Case study; Toxicity; Human</ED>
<EG>Methyltransferases; Transferases; Enzyme; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Digestive diseases</EG>
<SD>Parkinson enfermedad; Entacapona; Antiparkinsoniano; Inhibidor enzima; Catechol O-methyltransferase; Hígado patología; Estudio caso; Toxicidad; Hombre</SD>
<LO>INIST-20953.354000105559450350</LO>
<ID>03-0038722</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002587 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002587 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0038722
   |texte=   Entacapone-induced hepatotoxicity and hepatic dysfunction
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Entacapone-induced hepatotoxicity and hepatic dysfunction

Entacapone-induced hepatotoxicity and hepatic dysfunction

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri